Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 6/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9688663 | 0.87 | TOP2A (0.55) | TOP2ATOP2BKCNH2MEN1KMT2A | |
| SCHEMBL9088413 | 0.86 | TOP2A (0.48) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| SCHEMBL7576170 | 0.85 | STAT3 (0.44) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| SCHEMBL13581390 | 0.85 | TOP2A (0.51) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| SCHEMBL14143512 | 0.85 | TOP2A (0.51) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| SCHEMBL10379314 | 0.85 | TOP2A (0.44) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| SCHEMBL9278706 | 0.85 | TOP2A (0.44) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| SCHEMBL8131012 | 0.83 | TOP2A (0.37) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| SCHEMBL9090016 | 0.81 | KCNH2 (0.54) | TOP2ATOP2BKCNH2HRH3MEN1 | |
| Hydrochloric Acid SCHEMBL10440761 | 0.80 | KCNH2 (0.53) | TOP2ATOP2BKCNH2HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012144-B2 | Quinolone carboxylic acid derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-03-14 | — | — | US | disclosed |
| US-20030130302-A1 | Quinolone carboxylic acid derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-07-10 | — | — | US | disclosed |
| CN-1063747-C | Quinolone- and naphthyridonecarboxylic acid derivatives | BAYER AG (DE) | 2001-03-28 | — | — | CN | disclosed |
| EP-0704443-B1 | Quinolone and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 2000-12-27 | — | — | EP | disclosed |
| EP-0705828-B1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1999-12-01 | — | — | EP | disclosed |
| US-5990122-A | SUBSTITUTED IN THE 7-POSITION BY A TRICYCLIC AMINE RADICAL; REDUCED GENOTOXIC PROPERTIES AND INCREASED ANTIBACTERIAL ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-23 | — | — | US | disclosed |
| US-5986105-A | ENANTIOMORPHS AS BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | disclosed |
| US-5783708-A | HEXAHYDROISOINDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-21 | — | — | US | disclosed |
| US-5753669-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | disclosed |
| US-5703094-A | Quinolone- and naphthyridonecarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-30 | — | — | US | disclosed |
| US-5395944-A | Bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-03-07 | — | — | US | disclosed |
| EP-0326891-B1 | Antibacterial agents | WARNER LAMBERT CO (US) | 1994-08-03 | — | — | EP | disclosed |
| EP-0589318-A2 | Antibacterial 7-(aminomethyl-oxa-7-azabicyclo(3.3.0)oct-7-yl)quinolone- and -naphthyridonecarboxylic acid derivatives | BAYER AG (DE) | 1994-03-30 | — | — | EP | disclosed |
| EP-0550016-A1 | Novel quinolone carboxylic acid derivatives and processes for preparing same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-07-07 | — | — | EP | disclosed |
| EP-0398967-A1 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1990-11-28 | — | — | EP | disclosed |
| CN-1045972-A | 5-replaces-1,4-dihydro-4-oxo-naphthyridine-3-carboxylic acid (ester) antimicrobial drug | BRISTOL MYERS SQUIBB CO (US) | 1990-10-10 | — | — | CN | disclosed |
| EP-0387802-A2 | 5-Substituted-1,4-dihydro-4-oxonaphthyridine-3-carboxylate antibacterial agents | Bristol-Myers Squibb Company (US) | 1990-09-19 | — | — | EP | disclosed |
| US-4920120-A | 3-CARBOXY, 4-OXO, 6-FLUORO, 7-NITROGEN-CONTAINING RING 1,4-DIHYDRO-1,8-NAPHTHYRIDINES | WARNER-LAMBERT COMPANY (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0326891-A2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| WO-1989006649-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130302-A1 | Quinolone carboxylic acid derivatives | CYCS, CBR3, HCCS | TOP2A 257/4885TOP2B 328/4885KCNH2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.